Disease modifying agents capable of controlling obesity with meaningful metabolic improvement have reshaped expectations for both clinicians and patients ( Nausea and vomiting remain among the most frequent and disruptive adverse effects across Glucagon-like peptide (GLP-1)-based therapies ( In this opinion article, we examine the mechanisms underlying nausea and vomiting in semaglutide, CagriSema, survodutide, tirzepatide, retatrutide, and orforglipron and situate them within obesity clinical practice ( We also propose practical strategies to mitigate gastrointestinal intolerance
About 5-Amino-1MQ 5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the regulation of cellular energy metabolism and NAD+ biosynthesis
Use of GLP-1 receptor agonists in pregnancy
People are interested in pills, but still have questions: Before learning more about the treatments, most non-users said they would prefer a tablet over an injection
To retain the resolution of the monocytes and lymphocytes it is essential that the density barrier layer is disturbed as little as possible after the centrifugation
